Testing effectiveness (Phase 2)Study completedNCT00857493
What this trial is testing
Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects
Who this might be right for
Smallpox
Bavarian Nordic 120